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Background: The successful gene delivery into the brain is a major challenge due to the presence of the blood–brain
barrier (BBB). In order to transport plasmid DNA across the BBB and target the brain glioma, the PEGylated liposomes
(PLs) modified with OX26 and chlorotoxin (CTX) were developed as a dual-targeting gene delivery system, and the
therapeutic efficacy of OX26/CTX-PL/pC27 against glioma was evaluated using in vitro and in vivo experimental models.
Methods: The PEGylated liposome complexes were prepared by the reverse phase evaporation method, and their
physicochemical properties were examined. The transfection efficiency, intracellular distribution, in vitro effects of
OX26/CTX-PL/pC27 were determined on C6, F98 and HEK293T cell lines. The dual-targeting therapeutic efficacy of
OX26/CTX-PL/pC27 against glioma were assessed using the BMVECs/C6 cells co-culture model and the rat orthotopic
glioma model.
Results: The OX26/CTX-PL/pDNA complexes exhibited a subglobose shape, and possessed notably low toxicities to
HEK293T and C6 cells post 4 h incubation. In the in vitro transfection experiment, gene expressions of hTERTC27 from
C6 and F98 cells were significantly improved by OX26 and CTX modification. Our in vitro results also showed that OX26
endowed the PLs with the transport ability across the BBB. Using the BMVECs/C6 cells co-culture model, the viability of
C6 cells was decreased to 46.0% after OX26/CTX-PL/pC27 transfection. The OX26/CTX-PL/pC27 complexes exhibited
enhanced therapeutic effects on C6 cells. Moreover, the dual-targeting therapeutic effects were further conformed
with diminished tumor volumes (18.81 ± 6.15 mm3) and extended median survival time (46 days) in C6 glioma-bearing
rats. Immunohistochemical analysis revealed the therapeutic effects derived from enhanced hTERTC27 expression in
the tumor site.
Conclusions: The PEGylated liposomes modified with OX26 and CTX are able to significantly promote cell transfection,
increase the transport of plasmid DNA across the BBB and afterwards target the brain glioma cells in vitro and in vivo,
exhibit the most significant therapeutic efficacy. The ligand OX26 plays a critical role in transporting the lipoplexes
across the BBB, and CTX acts as a major role in targeting brain glioma cells. The results would encourage further
developments for non-invasive targeting therapy of brain gliomas by intravenous injection.
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Gliomas are the most frequent primary intracranial tu-
mors in adults, and the yearly incidence is six cases per
100 000 [1]. The high-grade glioma, glioblastoma multi-
forme (GBM), almost invariably infiltrates the surround-
ing normal brain tissue, which makes it impossible for a
complete surgical tumor removal, and is typically associ-
ated with rapid progression and a fatal outcome [2]. An-
other obstacle for the treatment of GBM is the presence
of the blood–brain barrier (BBB), which prevents nearly
all large-molecule drugs and more than 98% of small-
molecule pharmaceuticals entering the brain tissue [3].
Over the past 3 decades, the standard treatment has
evolved to include maximal safe surgical resection, radiation
therapy and temozolomide chemotherapy, while the median
survival of GBM patients only achieves 14.6 months. GBM
remains to be lethal for most of the patients [4,5].
Alternatively, gene therapy may offer a promising cure
for various diseases including GBM. To obtain a better
therapeutic effect, a gene delivery system is urgent for
clinic employ to transport genes across the BBB and
then target the brain glioma.
Liposomes, as an effective gene vehicle, are rapidly elim-
inated from the blood circulation by the mononuclear
phagocyte system (MPS) after intravenous administration
[6-8]. By conjugating polyethyleneglycol (PEG) to the sur-
face of liposomes, the PEG outer shell can reduce protein
opsonization and subsequent phagocytosis by the MPS,
resulting in an increased circulation time [9]. This kind of
sterically stable, long-circulating liposomes have led to a
new era in the liposome drug delivery [10-12]. By coupling
with targeting antibodies, peptides, and small molecules,
such as OX26 [13], transferring (Tf) [14], angiopep-2 [15]
and folate [16], the pegylated liposomes can actively target
the tumor sites. Such a targeting gene delivery system is
characterized with a high stability of the encapsulated
DNA under physiological conditions and a prolonged cir-
culation half life in vivo, and finally exerts greater antitu-
mor activities, compared with the conventional liposomes
loaded with therapeutic genes [8,17,18].
The transferrin receptor (TfR) is abundant on the
brain capillary endothelium, one component of the BBB,
and therefore the TfR monoclonal antibody (mAb) of
rats, OX26, is able to bind to an extracellular domain of
TfR and transport across the BBB via the endogenous
transferrin transport system [17,19]. And since the bind-
ing domain of OX26 is distinct from the transferrin
binding site, it does not interfere with Tf binding under
physiological conditions [20]. Thus, the OX26 is a very
efficient targeting antibody candidate in brain drug de-
livery [21]. However, the TfRs express not only on the
BBB and tumor cells, but also on neuronal plasma mem-
brane as well as other organs, such as liver and spleen.
As a result, the expression of exogenous plasmid DNAfor this strategy reaches throughout the central nervous
system, leading to a lack of the specific targeting to the
tumor tissue [13,17,22].
Chlorotoxin (CTX), originally isolated from Leiurus
quinquestriatus venom, is a 36-amino acid peptide tightly
folded via four disulfide bridges. Several researches have in-
dicated that CTX specifically binds to gliomas and tumors
of neuroectodermal origin rather than non-neoplastic cells
or normal brain [23,24], and this specific binding to cancer
cells is facilitated by matrix metalloproteinase-2 (MMP-2)
[25]. These characteristics make this molecule an attractive
targeting candidate for the diagnosis and treatment of tu-
mors [26,27].
hTERTC27, a 27 kDa C-terminal polypeptide of human
telomerase reverse transcriptase (hTERT), is capable of
inducing telomere dysfunctions, anaphase chromosome
end-to-end fusions in hTERT-positive HeLa cells, and in-
hibits HeLa cell growth and tumorigenicity in nude mice
xenografts [28]. Especially, hTERTC27 takes effect without
perturbing the endogenous telomerase activity, thereby
minimizing the potential side effects on telomerase posi-
tive reproductive cells and proliferative cells of renewal
tissues in anti-telomerase therapies [29,30].
In the present study, we developed a dual-targeting
system, plasmid IRES2-EGFP/hTERTC27 (pC27)-loaded
PEGylated liposomes (PLs) modified with OX26 and
CTX (OX26/CTX-PL/pC27) as a platform for the target-
ing delivery of pC27 to glioma. This system is expected
to transport pC27 across the BBB and then target brain
glioma mediated by OX26 and CTX, respectively. The
objective of this study is to determine the therapeutic effi-
cacy of OX26/CTX-PL/pC27 in the treatment of glioma.
Results and discussion
Successful gene delivery into the brain is a major chal-
lenge due to the presence of the BBB. Over the last dec-
ade, a number of ligands, such as OX26, folate and
angiopep-2, have been verified capable of specifically
binding to surface receptors on the target sites, resulting
in increased selectivity [31,32]. Accordingly, there have
been great developments concerning the brain drug de-
livery systems [14,33,34]. However, most of them are de-
veloped for delivering daunorubicin, paclitaxel, or other
widely used chemotherapeutics in glioma therapy. In the
present study, we employed the PEGylated liposomes as
the delivery vector of plasmid DNA and constructed the
dual-targeting gene delivery system.
OX26-PL/pDNA, OX26/CTX-PL/pDNA complexes were
prepared through the outer maleimide groups of PLs specif-
ically reacting with the thiol groups of OX26-SH and CTX-
SH (Figure 1). To explore the effects of the ratios of
DC-chol to pDNA on the particle size and zeta poten-
tial, we prepared PL/pDNA complexes with different
weight ratios under the condition of fixing the amount
Figure 1 The schematic diagram for the synthesis of targeting PL/pDNA complexes. (A) The OX26 and CTX were thiolated by 2-iminothiolane
(Traut’s reagent) at room temperature for 1 hour. (B) The outer maleimide groups of PL/pDNA react with the thiolated OX26 and CTX to form targeting
PL/pDNA complexes.
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chol/pDNA reached 6:1, the particle size tended to be
stable (Additional file 1: Figure S1).
The mean particle size of all PL/pDNA complexes was
approximately 120 nm, with an appropriate polydisper-
sity index (PDI, approximately 0.2). All of the charge
values were positive, and this guaranteed high pDNA en-
capsulation efficiency by electrostatic attraction of op-
posite charges (Additional file 2: Table S1). The PL/
pDNA complexes exhibited subglobose shape of moder-
ate uniform particle size and there was no aggregation
phenomenon of the particles. The particle size measured
from the TEM images was in good agreement with that
measured by the laser scattering method (Additional file
3: Figure S2). No significant change in the mean particle
size of the liposome complexes was detectable after
1 week when kept in PBS at 4°C. In DMEM containing
10% FBS, the liposome complexes remained stable in
terms of size for 8 h at 37°C (data not shown).
The size of particles plays a critical role in their clear-
ance by the spleen. Since the interendothelial cell slit
(IES) size of the spleen rarely exceeds 200 to 500 nm in
width, particles must be either small or deformable enough
to avoid the splenic filtration through the IES of venous si-
nuses. Therefore ideally, the size of particles should not ex-
ceed 200 nm [35,36]. Besides, it has been reported that the
nanoparticles with a mean diameter approximately 100 nm
showed prolonged blood circulation and a relatively low
rate of MPS uptake [37]. The mean diameter of the differ-
ent PL/pDNA complexes in this study was approximately
120 nm, which satisfied the size requirements described
above. The prolonged blood circulation attributed to make
more nanoparticles reach the brain and achieved enhanced
permeability and retention (EPR) effects.
Positively charged particles can fully condense and
coat DNA, thus avoiding the degradation of DNases[38]. However, such particles tend to form small aggre-
gates in the presence of the negatively charged serum
proteins once i.v. administered and often exhibit a
rapid blood clearance phase with a large dose accumu-
lating in the lung and the liver. Grafting neutral PEG
onto the surface of the cationic liposomes prevents aggre-
gation and increases their stability due to the charge
shielding [39].
The encapsulation efficiency of all lipoplexes was show
in Additional file 4: Table S2. Compared with PL/pEGFP
or PL/pC27, the encapsulation efficiency of OX26-PL/
pDNA, OX26/CTX-PL/pDNA decreased to some extent.
It may be a consequence of pDNA releasing from com-
plexes during the reaction between OX26, CTX and PL/
pDNA. The coupling efficiencies of OX26 in OX26-PL/
pC27, OX26/CTX-PL/pC27 were 40.4 ± 5.1% and 35.4 ±
3.8%, respectively. The coupling efficiencies of CTX in
CTX-PL/pC27, OX26/CTX-PL/pC27 were 44.9 ± 6.1% and
42.5 ± 5.5%, respectively. There was no obvious interaction
between OX26 and CTX during the coupling reaction.
The cytotoxicity of the PL/pEGFP, OX26-PL/pEGFP
and OX26/CTX-PL/pEGFP complex at a series of plasmid
weights were evaluated with CCK-8 Kits in HEK293T and
C6 cells (Additional file 5: Figure S3). Cell viability de-
creased as the weight of pEGFP in the complex increased.
For HEK293T, cell viability of OX26/CTX-PL/pEGFP
group was 94.05% ± 0.43% and 82.94% ± 0.41% at 0.1 μg
and 1.6 μg pEGFP, respectively. For C6, cell viability was
93.67% ± 0.47% and 81.89% ± 0.44% at 0.1 μg and 1.6 μg
pEGFP, respectively. The PL complexes showed notably
low toxicity to the HEK293T and C6 cells after 4 h incuba-
tion, which might be attributed to the similarity of the li-
posomes to the cell membranes and the charge-shielding
effects of PEG chains. No statistical differences in the cell
viability were found among PL/pEGFP, OX26-PL/pEGFP
and OX26/CTX-PL/pEGFP at the corresponding plasmid
Figure 2 Transfection efficiency of Lipo2000/pEGFP, PL/pEGFP,
OX26-PL/pEGFP and OX26/CTX-PL/pEGFP complexes
containing 1 μg pIRES2-EGFP by FACS analysis in (A) HEK293T
cells, (B) C6 glioma cells, (C) F98 glioma cells. Data are expressed
as mean ± SD (n = 3).
Yue et al. Molecular Cancer 2014, 13:191 Page 4 of 13
http://www.molecular-cancer.com/content/13/1/191weights except OX26/CTX-PL/pEGFP at 1.6 μg pEGFP
(p < 0.01 compared with that of PL/pEGFP and OX26-PL/
pEGFP, respectively).
The transfection efficiency of complexes was visualized
by observation of EGFP positive cells using a fluores-
cence microscope. For HEK 293 T cells, no obvious dif-
ferences of the fluorescent density were observed among
PL/pEGFP, OX26-PL/pEGFP and OX26/CTX-PL/pEGFP
containing 1 μg pEGFP. For C6 and F98 cells, the high-
est transfection efficiency was found in OX26/CTX-PL/
pEGFP complex while the weakest fluorescent density
was displayed in PL/pEGFP complex at 1 μg pEGFP
(Additional file 6: Figure S4). The transfection efficiency
was further quantified by the flow cytometry assay.
When HEK293T cells were transfected with Lipo2000/
pEGFP, PL/pEGFP, OX26-PL/pEGFP and OX26/CTX-
PL/pEGFP complexes at 1 μg pEGFP, the average ratios
of EGFP-positive cells were 84.2%, 44.3%, 43.2% and
44.3%, respectively (Figure 2A). However, the average ra-
tios were 35.2%, 20.6%, 27.4% and 31.2% for C6 cells,
and 42.6%, 24.3%, 31.3% and 36.1% for F98 cells, re-
spectively (Figure 2B, 2C). No significance on transfec-
tion efficiency was shown in HEK 293 T cells (p > 0.05),
while compared with that of PL/pEGFP for C6 and F98
cells, higher transfection efficiencies of OX26-PL/pEGFP
and OX26/CTX-PL/pEGFP were indicated (p < 0.01)
(Figure 2). This was probably attributed to the absence
of the corresponding receptors of OX26 or CTX on
HEK293T cells, and the recognition of OX26 to TfR,
CTX to MMP-2 in C6 and F98 cells (both TfR and
MMP-2 are over expressed in the rat glioma cells).
To quantify the transgene expression level, luciferase
reporter assays were carried out. As the increase of the
weight of pGL3-luc, enhanced luciferase activities were
shown among Lipo2000/pGL3-luc, PL/pGL3-luc, OX26-
PL/pGL3-luc and OX26/CTX-PL/pGL3-luc. For C6 and
F98 cells, OX26-PL/pGL3-luc and OX26/CTX-PL/pGL3-
luc complexes obtained obvious higher luciferase activities
than the PL/pGL3-luc complexes among all the tested
weights of pGL3-luc, and there was also obvious differ-
ence between OX26-PL/pGL3-luc and OX26/CTX-PL/
pGL3-luc (Additional file 7: Figure S5B, C), indicating that
the novel OX26/CTX-PL/pGL3-luc complexes increased
the transgene expression due to its targeting ligands. No
differences were found in luciferase activities among
the three complexes above in HEK293T cells (p > 0.05)
(Additional file 7: Figure S5A). Consistent with results
from the flow cytometry assay, this further proved the
possible targeting effect of OX26 and CTX.
Intracellular expression and distribution of hTERTC27
was observed by virtue of confocal microscope (Additional
file 8: Figure S6). The expression of hTERTC27 presented
in a time-dependent manner. With extension of culture
time, positive cells and fluorescence intensity of geneexpression increased. The hTERTC27 protein distrib-
uted throughout the C6 cells, though primarily within
the cell nuclei.
To explore the potential therapeutical effect of OX26/
CTX-PL/pC27 complex, its cytotoxicity was initially
evaluated at a series of plasmid concentrations in C6
glioma cells by CCK-8 assay. As shown in Figure 3A,
reduction of cell viability was shown with the in-
crease of weight of pIRES2-hTERTC27 in the com-
plex. Figure 3B showed the viability of C6 glioma cells
Figure 3 The therapeutical effect of OX26/CTX-PL/pC27
complex and western blot analysis. (A) The cell viability of the C6
glioma cells after transfection of OX26/CTX-PL/pC27 complex at a
series of plasmid weights. (B) The viability of C6 glioma cells after
transfection of OX26/CTX-PL/pEGFP, PL/pC27, OX26-PL/pC27 and
OX26/CTX-PL/pC27 at 0.2 μg pDNA. (C) Western blot analysis of the
expression of hTERTC27 in C6 glioma cells after transfections of
OX26/CTX-PL/pEGFP, PL/pC27, OX26-PL/pC27 and OX26/CTX- PL/
pC27complexes at 4 μg pDNA. OX26/CTX-PL/pEGFP was set as the
negative control.
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PL/pC27 at 0.2 μg pC27 (81% ± 5%, 58% ± 3% and 47% ±
4.5%, respectively). Obviously, OX26-PL/pC27 and OX26/
CTX-PL/pC27 exhibited higher toxicity to C6 glioma cells
than PL/pC27, and there was also obvious difference be-
tween OX26-PL/pC27 and OX26/CTX-PL/pC27 (p = 0.04).
The results indicated that the strength of antitumor ef-
fects was OX26/CTX-PL/pC27 > OX26-PL/pC27 > PL/
pC27. The results may be explained by the higherhTERTC27 protein level in the OX26/CTX-PL/pC27 and
OX26-PL/pC27 treatment groups (Figure 3C). Therefore,
we concluded that targeting ligands OX26 and CTX pro-
moted cell transfection of lipoplexes, increased hTERTC27
protein expression, and enhanced the therapeutical effect
on C6 cells.
In vitro BBB model was established and confirmed by
the permeation experiment and transendothelial elec-
trical resistance (TEER) values (>250 Ωcm2). No obvious
reduction of TEER values was observed during the ex-
periment, indicating that transport of pC27 did not dis-
rupt the BBB barrier. Figure 4A showed the transport
ability of different lipoplexes across BBB model at the
same concentration of pDNA. The transport ratios were
3.23% for PL/pC27, 6.50% for OX26-PL/pC27, 6.42%
for OX26/CTX-PL/pC27, 3.08% for PL/pC27 precondi-
tioned with OX26, 3.00% for OX26-PL/pC27 precondi-
tioned with OX26, 3.13% for OX26/CTX-PL/pC27
preconditioned with OX26 at 4 h, respectively. When
the model was pre-incubated with free OX26 to saturate
the TfR on the BBB, the transport ratios of OX26-PL/
pC27 and OX26/CTX-PL/pC27 decreased significantly,
which displayed no difference with that of PL/pC27. There
was no obvious alternation for PL/pC27 preconditioned
with and without OX26. The results revealed OX26 modi-
fication on the PL/pDNA complexes played a critical role
in the transport assay while CTX did not exert effect on
the transport across BBB, and the increased transport abil-
ity of the PL modified with OX26 may be mediated by
TfR. Our results were supported with the research that
the TF-conjugated liposomes were able to increase the de-
livery of drug across the BBB mediated by TfR [40].
To evaluate the dual-targeting effects in vitro, the tox-
icity test of the lipoplexes on C6 glioma cells after cross-
ing the BBB was conducted with the BBB/C6 co-culture
model. As shown in Figure 4B, the viability of C6 cells
were 89.9% for PL/pC27, 59.7% for OX26-PL/pC27,
46.0% for OX26/CTX-PL/pC27, 88.1% for PL/pC27 pre-
conditioned with OX26, 79.0% for OX26-PL/pC27 pre-
conditioned with OX26, 74.1% for OX26/CTX-PL/pC27
preconditioned with OX26, respectively. The OX26/
CTX-PL/pC27 complexes exhibited enhanced cytotox-
icity. Furthermore, after pre-incubation with OX26, the
cytotoxicity of OX26/CTX-PL/pC27 was notably re-
duced and no differences were displayed, compared with
that of PL/pC27, and OX26-PL/pC27 (p > 0.05). The re-
sults indicated evident dual-targeting effects of OX26/
CTX-PL/pC27 due to the elevated endocytosis mediated
by the specific binding CTX to MMP-2, following the
increased transport across the BBB by the specific bind-
ing OX26 to TfR.
The rat C6 glioma models were employed in our study
for further verifying the dual-targeting treatment effect
of OX26/CTX-PL/pC27 in vivo (Figure 5A~ F). The average
Figure 4 Transport ratios across the BBB and dual-targeting effects in vitro. (A) The transport ratios of pC27 across the BBB during 1 ~ 4
hour. (B) The cell viability of C6 cells after pC27 transported across the BBB. Data were presented as mean ± SD (n =3). *p < 0.01, vs. PL/pC27.
Figure 5 Dual-targeting effects of OX26/CTX-PL/pC27 complex and survival monitoring in vivo. (A) ~ (F): the cross-sections of the rat brain
among different treatment groups. (A) sham-operated group (without C6 cells or drug administration); (B) PBS control group; (C) OX26/CTX-PL/
pEGFP control group; (D) PL/pC27 group; (E) OX26-PL/pC27 groups; (F) OX26/CTX-PL/pC27 group. The red arrows designated the tumor
sites. (G) The tumor volumes of the C6 glioma bearing rats among different treatment groups. Data were presented as mean ± SD
(n = 6). *p > 0.05, **p < 0.01, vs. OX26/CTX-PL/pEGFP. (H) The Kaplan-Meier survival curves of C6 glioma bearing rats treated with PBS, OX26/
CTX-PL/pEGFP, PL/pC27, OX26-PL/pC27 and OX26/CTX-PL/pC27complexes after inoculation, respectively.
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group, 47.1 ± 3.02 mm3 for OX26/CTX-PL/pEGFP group,
44.87 ± 3.12 mm3 for PL/C27 group, 33.49 ± 2.83 mm3 for
OX26-PL/pC27 group and 18.81 ± 6.15 mm3 for OX26/
CTX-PL/pC27 group, respectively. As shown in Figure 5G,
the OX26/CTX-PL/pC27 therapy significantly diminished
the tumor size when compared with the controls (p < 0.01),
PL/pC27 (p < 0.01) and OX26-PL/pC27 therapy (p < 0.05).
On the contrary, OX26/CTX-PL/pEGFP did not exhibit in-
hibitory effects on the tumor, compared with the PBS con-
trol (p > 0.05). Treatment effects of different PL complexes
were also reflected by the Kaplan-Meier survival
curves (Figure 5H). The median survival time of rats
treated with OX26/CTX-PL/pC27complexes (46 days)
was significantly longer than that of rats treated with
PBS (13 days, p = 0.000), OX26/CTX-PL/pEGFP (14 days,
p = 0.000), PL/pC27 (21 days, p = 0.002) and OX26-PL/
pC27 (29 days, p = 0.038), respectively. These results indi-
cated that OX26-PL/pC27 was able to improve the treat-
ment efficacy while the dual-targeting OX26/CTX-PL/
pC27 led to the most significant tumor inhibition and the
most significant improvement in the median survival time
of tumor-bearing rats. These findings offered the robust
evidence for the dual-targeting therapeutic effects.
To observe the histopathological changes and confirm
the expression of the hTERTC27 protein, HE staining
and IHC analysis were conducted. The hTERTC27
histochemistry showed that the gene was expressed
only in the tumor site by EPR effects in the PL/pC27
group (Additional file 9: Figure S7B), and widely expressed
throughout the brain in the OX26-PL/pC27 group
(Additional file 9: Figure S7C). However, compared
with that of the OX26-PL/pC27 group, the hTERTC27
protein mainly occurred in the tumor site and there
was marked reduction in the expression out of the tumor
site in the OX26/CTX-PL/pC27 group (Additional file 9:
Figure S7D). As shown in Figure 6(A1 ~ F1), all glioma tis-
sues were hypercellular with abundant cytoplasm, nuclear
pleomorphism and partly with large nucleolus. In the
OX26-PL/pC27 group, vacuolization was observed in
most of the tumor cells and small, scattered necrosis
happened sometimes (Figure 6E1). However, apoptotic
bodies, nuclear fragments and massive necrosis oc-
curred on the basis of the vacuolization in the OX26/
CTX-PL/pC27 group (Figure 6F1). Further IHC study
was performed to observe the expression of the
hTERTC27 protein in the tumor cells and normal cells
adjacent to cancer. The nuclei were stained blue and no
hTERTC27 distributed in the tumor cells both in the PBS-
control and OX26/CTX-PL/pEGFP groups (Figure 6B2,
C2). In the PL/pC27, OX26-PL/pC27 and OX26/CTX-PL/
pC27 groups, immunostaining of hTERTC27 protein was
visualized throughout the cell, though primarily in the cell
nuclei of glioma, and the scores were 1.33 ± 0.58, 7.33 ± 1.16and 11.00 ± 1.73 in tumor cells while the scores were 0,
3.33 ± 1.15 and 8.00 ± 1.73 in normal cells, respectively
(Figure 6D2 ~ F3). The staining score of tumor cells in
the OX26/CTX-PL/pC27 group was significantly higher
than that in PL/pC27 (p < 0.01) and OX26-PL/pC27groups
(p = 0.034). On the contrary, the normal cells scored in the
OX26/CTX-PL/pC27 group much lower than in the
OX26-PL/pC27group (p < 0.01), which was consistent with
the result of hTERTC27 gross distribution in rat brains.
Immunohistochemical analysis further revealed the thera-
peutic effects derived from hTERTC27 expression in the
tumor site.
In a word, compared with the existing studies, our
dual-targeting delivery system was designed with the fol-
lowing features: (1) this system was of low toxicity and
good biocompatibility; (2) the dual-targeting delivery in-
creased therapeutic gene expression in the tumor site
and improved the drug utilization; (3) intravenous ad-
ministration avoided the damage caused by local injec-
tion and conformed to the development direction of
nanocarriers; (4) the PEGylated liposomes, dual-targeting
delivery, gene therapy and intravenous administration
were fused together, and achieved a new breakthrough for
the treatment of the glioma.
Conclusions
The PEGylated liposomes modified with OX26 and CTX are
able to significantly promote cell transfection, increase the
transport of plasmid DNA across the BBB and afterwards
target the brain glioma cells in vitro and in vivo, exhibit the
most significant cytotoxicity in vitro and therapeutic efficacy
in brain glioma-bearing rats. The ligand OX26 plays a critical
role in transporting the lipoplexes across the BBB, and CTX
acts as a major role in targeting brain glioma cells. Further-
more, OX26 also contributes to the glioma-targeting effect
of the lipoplexes. The results would encourage further de-
velopments for non-invasive targeting therapy of brain gli-
omas by intravenous injection.
Materials and methods
Materials
Soybean phosphatidylcholine (S100-PC) was purchased
from Lipoid GmbH (Ludwigshafen, Germany). DC-chol,
2-Iminothiolane hydrochloride (2-IT, Traut’s reagent),
CTX and sulforhodamine B (SRB) were provided by
Sigma-Aldrich (Saint Louis, MO, USA). Mal-PEG2000-
DSPE was obtained from Avanti Polar Lipids (Alabaster,
AL, USA). Anti-Transferrin Receptor antibody (OX-26)
and anti-Telomerase reverse transcriptase antibody were
purchased from Abcam (Cambridge, UK). Sephadex G-50
and Sepharose CL-4B were provided by Science and Tech-
nology Development Co., Ltd. (Beijing, China). Centriprep-
10 concentrators were purchased from Millipore Amicon
(Bedford, MA, USA). NanoOrange® Protein Quantitation
Figure 6 HE staining (A1 ~ F1) and immunohistochemistry (A2 ~ F3) of brain tissues from the C6 glioma bearing rats (×400). A (A1, A2):
Normal brain; B (B1, B2): PBS-control; C (C1, C2): OX26/CTX-PL/pEGFP group; D (D1, D2, D3): PL/pC27 group; E (E1, E2, E3): OX26-PL/pC27 group;
F (F1, F2, F3): OX26/CTX-PL/pC27 group. D2, E2, F2 were from tumor cells; D3, E3, F3 were from normal cells adjacent to cancer.
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YOYO-1 and LysoTracker Red were purchased from
Molecular Probes (Eugene, OR, USA). pIRES2-EGFP
(pEGFP) and pIRES2-EGFP/hTERTC27 (pC27) were
purified using a E.Z.N.A.TM Fastfilter Plasmid Maxi
Kit (Omega, Norcross, GA, USA). Cell Counting Kit-8
(CCK-8) was purchased from Dojindo Molecular Tech-
nologies (Tokyo, Japan). Lipofectamine™ 2000 Reagent
(Lipo2000) was purchased from Invitrogen (California,
USA). pGL3 Luciferase Reporter Vectors (pGL3-luc)
and Luciferase Reporter Assay Kit were purchased
from Promega (Madison, WI, USA).Cell culture
The C6, F98 glioma cells and human embryonic kidney
293 T (HEK 293 T) cells were obtained from ATCC
(American Type Culture Collection, VA, USA) and were
cultured in high glucose Dulbecco’s modified Eagle’s
medium (DMEM, Gibco) supplemented with 10% fetal
bovine serum (FBS, Gibco), 100 U/ml penicillin and
100 μg/ml streptomycin at 37°C in a humidified 5% CO2
incubator. Brain microvascular endothelial cells (BMVECs),
were isolated from bovine brain and cultured in endothelial
cell culture medium (DMEM, 20% FBS, 100 U/ml peni-
cillin, 100 μg/ml streptomycin, 2 mmol/L L-glutamine,
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heparin, and 40 μU/mL insulin) [41].
Animals
Male Wistar rats (250-280 g) were supplied by Laboratory
Animal Center of Sun Yat-sen University (Guangzhou,
China) and were housed in air-conditioned rooms
(temperature: 21 ± 2°C; humidity: 55 ± 4% and light:
12 h light/dark cycle). All animal experiments were
carried out with the approval of the Ethics Committee
of Sun Yat-sen University.
Preparation and characterization
Pegylated liposomes (PLs) synthesis and plasmid DNA
encapsulation
PLs were prepared by reverse phase evaporation method
as described previously [42,43]. Briefly, 25.1 mg S100-PC,
19.9 mg DC-chol, 10.5 mg DSPE-PEG, 8.8 mg Mal-
PEG2000-DSPE were dissolved in chloroform. The solu-
tion was then evaporated using rotary evaporation to form
thin lipid film at room temperature. The dried lipid film
was subsequently re-dissolved in chloroform and 0.5 mg
plasmid of pEGFP or pC27 in 1 mL PBS was added. After
vortex and ultrasonication at 10°C for 5 min, respectively,
the solution was evaporated at 30°C to form a transparent
and opalescence aqueous phase. The aqueous phase was
extruded by turns through a 400 nm, 200 nm and 100 nm
polycarbonate filter for 4 times, and the unmodified
PL/pEGFP and PL/pC27 were formed. The encapsulation
efficiency was determined as described previously [44].
Preparation of OX26 and/or CTX-conjugated liposome
complexes
The OX26 and CTX were thiolated by using a 40:1
molar excess of 2-iminothiolane (Traut’s reagent) at
room temperature for 1 hour, as described previously
[6]. The thiolated OX26 and CTX (OX26-SH and CTX-
SH) were incubated with PL/pEGFP and PL/pC27 (the
weight ratio of peptide to phospholipid was 1:20) over-
night at room temperature [45]. The targeting liposome
complexes were separated using a Sepharose CL-4B col-
umn and eluted with 0.001 M PBS buffer (PH 7.4) from
the reaction mixture [46]. The amount of uncoupled
OX26 or CTX was determined according to the NanoOr-
ange® Protein Quantitation Kit (Invitrogen Corporation,
USA) [47]. The total and uncoupled amounts of OX26 or
CTX were signed C0 and C1, respectively, coupling effi-
ciency (CE) was calculated by the formula: CE = (1 −C1/
C0) × 100%.
Particle size distribution, zeta potential and stability of
liposome complexes
After the liposome complexes were dispersed in deionized
water to make the solution with the final concentration of0.25 mg/mL, the particle size distribution and zeta poten-
tial were determined by the light scattering method using
a Zeta Potential/Particle Size analyzer (Zetasizer Nano
ZS90, Malvern, UK) with a scattering angle of 90° at 25°C
[48]. The morphology of the liposome complexes were
observed using transmission electron microscopy (TEM)
(JEM-2010, JEOL, Japan).
In order to determine the size stability of the liposome
complexes, the samples (10 mg/ml) were kept in PBS
(pH 7.4) (1:10, v/v) at 4°C for 1 week, and then the size
change was determined by the analyzer above [49]. In
addition, 100 μl samples (10 mg/ml) were added to 1 ml
culture medium containing 10% FBS, and incubated at
37°C for 8 h. At 1 h, 4 h and 8 h, the particle size was
measured to evaluate the variations in size [36].
In vitro cytotoxicity assay of the modified and unmodified
PL/pEGFP complexes
The cytotoxicity of the PL/pEGFP, OX26-PL/pEGFP and
OX26/CTX-PL/pEGFP complexes was measured by CCK-
8 assay. C6, HEK293T cells were seeded in a 96-well cul-
ture plates (Corning-Coaster, Tokyo, Japan) at 7000 cells
per well in 100 μl DMEM medium for 24 h to achieve
about 70% confluence. The medium was then replaced
with 200 μl solution of different liposome complexes,
which were loaded with a series of weights of pEGFP
(0.1 μg, 0.2 μg, 0.4 μg, 0.8 μg, 1.2 μg, 1.6 μg), for 4 h. Then,
cytotoxicity was performed using CCK-8 Kit. Cells with-
out treatment were used as control. Absorbance was mea-
sured at 450 nm and corrected at 630 nm by dual wave
length detection with TECAN Infinite M200 microplate
reader (Tecan, Durham, USA). Cell viability of each group
was expressed as a percentage relative to that of control.
In vitro transfection experiment
C6, F98 and HEK293T cells were incubated in 24-well
plates for 24 h to reach about 70% confluence. Before
transfection, the medium was removed and the cells
were washed 2 times with PBS. The cells were incubated
with PL/pEGFP, OX26-PL/pEGFP and OX26/CTX-PL/
pEGFP solutions containing 0.5 μg, 1 μg, 2 μg pEGFP in
serum-free DMEM medium for 4 h at 37°C. After ex-
changing with complete medium, the cells were further
incubated 48 h. The positive controls were treated with
Lipo2000/pEGFP solutions containing the corresponding
amounts of pEGFP while the negative one incubated
with PBS only. The fluorescent images were observed
and captured by the Eclipse TE2000-U fluorescence
microscope (Nikon, Tokyo, Japan). For transfection ef-
ficiency analysis, the cells were trypsinized, washed
and resuspended in 1.5 ml PBS. Transfection efficiency
was evaluated by scoring the percentage of cells ex-
pressing green fluorescence protein (EGFP) using a FACS
AriaTM System (Becton-Dickinson, San Joes, CA). The
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were counted in each experiment.
Luciferase reporter assay
Cells were transfected with the complexes containing
0.5 μg, 1 μg, 2 μg pGL3-luc in the 24-well plates in trip-
licate as described above. After 48 h of incubation, the
cells were lysed by 100 μl lysis buffer for each well. The
gene expression level in the lysates was evaluated using a
luciferase reporter assay kit with a luminometer (Lumat
LB9501 instrument, Bad Wildbach, Germany). The data
were expressed as relative light units (RLU) per well of
total cell protein.
Intracellular expression and distribution of hTERTC27
The C6 glioma cells were seeded at a density of 1 × 104
cells/well into 35 mm glass-bottom culture dishes (NEST,
Wuxi, China) and cultured overnight. Then the cells were
transfected with OX26/CTX-PL/pC27 solutions contain-
ing 4 μg pC27. C6 cells were washed three times with
PBS, fixed with 4% paraformaldehyde at 0, 12, 24, 48 h, re-
spectively. Then the cells were washed with PBS and incu-
bated with Lyso-Tracker Red (1:10000, 30 min) and DAPI
staining solution (5 min) to visualize the lysosomes and
nuclei, respectively. The prepared cells were observed
using laser scanning confocal microscope (Carl Zeiss
LSM700, Jena, Germany).
In vitro effects on C6 cells of the modified and
unmodified PL/pC27 complexes
The C6 glioma cells were transfected with OX26/CTX-
PL/pC27 complexes loading with a series of weights of
pC27 (0.1 μg, 0.2 μg, 0.4 μg, 0.8 μg, 1.2 μg, 1.6 μg) in
96-well culture plates. After the cells were cultured in
the complete DMEM culture medium for 48 h, cytotox-
icity was performed using CCK-8 Kit. The cytotoxicity
of PL/pC27, OX26-PL/pC27 and OX26/CTX-PL/pC27
containing 0.2 μg pC27 was also assessed by CCK-8 Kit.
Each experiment was repeated for three times.
Western blotting analysis
The C6 glioma cells were transfected with OX26/CTX-
PL/pEGFP, PL/pC27, OX26-PL/pC27 and OX26/CTX-
PL/pC27complexes containing 4 μg pDNA in 6-well
plates. After the cells were incubated with complete cul-
ture medium for 48 h and total protein was extracted.
Western blotting analysis was conducted as previously
described [16]. Briefly, protein samples (20 μg) were sep-
arated using SDS-PAGE and transferred onto polyvinyli-
dene difluoride (PVDF) membrane. The membrane was
incubated at room temperature for 1 hour in a blocking
buffer (5% low fat milk), and was then incubated with a
rabbit primary antibody (1:1000 dilution) against the
hTERTC27. Secondary antibody, horseradish peroxidase(HRP)-conjugated anti-rabbit IgG, was used to amplify the
signal. The blots were developed using chemiluminescence
system (New Life Science Products, Boston, MA, USA)
and the results were photo-documented.
In Vitro BBB model
The BBB model was established using BMVECs as de-
scribed previously [50]. Briefly, 2% gelatin was pre-
coated on 12-well cell culture inserts (polyethylene ter-
ephtalate membrane, 3 μm pore size, Millipore, Billerica,
USA) for 30 min. Then BMVECs were seeded into the
inserts at a density of 7.5 × 104 cells/insert on day 1. The
culture mediums were changed every other day. 4 h per-
meation assay was conducted and transendothelial
electrical resistance (TEER) values of the BBB were
measured with the TEER instrument (Word Precision
Instruments, Sarasota, FL, USA) on day 5. Only the BBB
models with no medium permeation in 4 h and the TEER
value over 250 Ωcm2 were included for experiments.
Transport across the BBB and competition assay
Lipoplexes, including PL/pC27, OX26-PL/pC27 and
OX26/CTX-PL/pC27, in which pC27 was labeled by
YOYO-1 [51], were added into the corresponding inserts
at the plasmid concentration of 50 μg/mL. For the com-
petition assay, excessive amount of OX26 (100 μg) was
added into the inserts in advance for 30 min, and then
cells were treated with PL/pC27, OX26-PL/pC27 and
OX26/CTX-PL/pC27. A volume of 400 μl sample was
taken from the acceptor compartments at 1, 2, 3, 4 h,
and 400 μl fresh medium was added immediately after
each sampling. The effects of all lipoplexes on BBB in-
tegrity were monitored by measuring TEER values dur-
ing the experiment. The BBB transport ratios of pC27
were determined by RF-5301PC fluorospectrophotome-
try (Shimadzu, Japan) with the excitation and emission
wavelength at 491 and 509 nm, respectively.
Dual-targeting effects in vitro
A BMVECs/C6 cells co-culture model was established as
previously reported [41]. The BBB model was established
and then the inserts were transferred to another 12-well
plate where C6 cells had been cultured for 1 day. Lipo-
plexes, including PL/pC27, OX26-PL/pC27 and OX26/
CTX-PL/pC27, were added into the inserts of the BBB
models at the plasmid concentration of 50 μg/mL for
4 h, respectively, and then inserts were removed. After
another 48 h, the survival percentage of C6 glioma cells
in the basolateral compartment was determined by SRB
stainig assay.
Dual-targeting effects and survival monitoring in vivo
Rat orthotopic glioma model was established as previously
described [16]. Briefly, male Wistar rats (250–280 g) were
Yue et al. Molecular Cancer 2014, 13:191 Page 11 of 13
http://www.molecular-cancer.com/content/13/1/191anesthetized with 10% chloral hydrate (4 ml/kg) and fixed
in a stereotactic apparatus (Huaibei Zhenghua Instru-
ments Co., Anhui, China). C6 glioma cells (1 × 106 cells
suspended in 10 μl PBS) were stereotactically implanted
into the right caudate nucleus (3 mm lateral and 1 mm
anterior to the bregma, 5 mm of depth) with a Hamilton
syringe (Shanghai Libao Instruments Co., Shanghai,
China).
At day 3 after the implantation, the rats were divided
into five groups (15 rats per group). Rats in blank con-
trol group were administered with PBS. Rats in the other
4 groups were treated with OX26/CTX-PL/pEGFP, PL/
pC27, OX26-PL/pC27 and OX26/CTX-PL/pC27com-
plexes via the tail vein at a dose of 40 μg pDNA per rat,
respectively. Administration was made every 3 days with
total 5 doses per rat. At day 18, six rats of each group
were sacrificed for measuring the tumor size. The tumor
volume was calculated by summing up the cross-
sectional areas using the formula: Volume = a2 × b × π/6
(a and b represent the width and length of the tumor).
The rest of rats were used for monitoring the survival
time, which was analyzed by the Kaplan-Meier survival
curve.
Histopathology and immunohistochemistry (IHC) study
Rat brains were collected and stored in 4% paraformal-
dehyde. The sections were cut at 3 ~ 5 mm thick from
paraffin-embedded brain tissue. After deparaffinization,
sections were stained with haematoxylin and eosin (HE).
IHC assay was performed using a standard two-step
technique as demonstrated previously [52]. Briefly, after
antigen retrieval was carried out by 4 minutes’ high
pressure method in Tris/EDTA buffer solution (pH 9.0),
the sections were incubated with 10% normal goat
serum at room temperature for 10 min to reduce non-
specific reaction. Subsequently, the sections were incu-
bated with anti-Telomerase reverse transcriptase antibody
(1:100) overnight at 4°C. The goat anti-rabbit IgG
antibody-HRP polymer (ZSGB-BIO, Beijing, China)
was used as a secondary link to DAB chromogen. Fi-
nally, the sections were counterstained with Mayer’s
hematoxylin. For the evaluation of hTERTC27 IHC
staining, a semi-quantitative scoring method was used
[53]. The staining intensity was scored as weak (1+),
moderate (2+), and strong (3+). The number of positive
staining cells were evaluated as follows: 0% (0), <10% (1),
10 ~ 50% (2), 51 ~ 80% (3); >80% (4). The staining index
(scores 0 ~ 12) for each case was obtained by multiplying
the values of the two parameters (percentage of the posi-
tive cells and predominant intensity).
Statistics analysis
Data were presented as mean ± standard deviation (SD).
One-way analysis of variance (ANOVA) was used todetermine significance among groups following the Bon-
ferroni’s post-test. p < 0.05 was considered to be
significant.
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and pEGFP (A) or pC27 (B) on the particle size and zeta potential of PL/
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the PL/pDNA complexes (n = 3).
Additional file 3: Figure S2. The TEM images of OX26/CTX-PL/pC27.
Scale bar represents 100 nm.
Additional file 4: Table S2. Encapsulation efficiency (EE) for the PL/
pDNA complexes (n = 3).
Additional file 5: Figure S3. The cell viability of the HEK293T and C6
cells after incubation with PL/pEGFP, OX26-PL/pEGFP and OX26/CTX-PL/
pEGFP complexes at 0.1, 0.2, 0.4, 0.8, 1.2, 1.6 μg of plasmid weights, re-
spectively. (A) HEK293T cells, (B) C6 glioma cells.
Additional file 6: Figure S4. Fluorescent microscopy images of
HEK293T cells, C6 and F98 gioma cells after transfection of Lipo2000/
pEGFP, PL/pEGFP, OX26-PL/pEGFP and OX26/CTX-PL/pEGFP complexes
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Additional file 7: Figure S5. Transfection efficiency of PL/pGL3-luc,
OX26-PL/pGL3-luc and OX26/CTX-PL/pGL3-luc complexes containing
0.5 μg, 1 μg, 2 μg pGL3-luc in (A) HEK293T, (B) C6 glioma cells, and
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expressed as mean ± SD (n = 3).
Additional file 8: Figure S6. Confocal images of C6 cells after
incubation with OX26/CTX-PL/pC27 for 0 h, 12 h, 24 h and 48 h. Blue
(DAPI), Red (Lyso-Tracker Red) and Green (EGFP) represent nuclei,
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Additional file 9: Figure S7. hTERTC27 distribution in rat brains
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